PROPHYLAXIS WITH KUZIK 2 TABLETS IN EPISODIC AND CHRONIC MIGRAINE: RETROSPECTIVE OBSERVATIONAL STUDY

Lo studio presentato al congresso sin bologna 2019

Kuzik® was well tolerated: in a numerical scale from 1 to 10 the average score was 9,5 ( range 8 -10) ; the compliance of patients was optimal, no side effect related to product were reported and no weight gain in patients occurred. A clear improvement of the patient’s asthenia should be noted. Regarding efficacy, at the end of treatment , in total population all parameters analyzed were significantly improved.

Our study clearly demonstrated the benefits, safety, and good tolerability of Kuzik® in the prophylaxis of migraine, with and without aura

STUDIO OSSERVAZIONALE IN APERTO SULL’EFFICACIA DI KUZIK® NELLA PROFILASSI DI PAZIENTI CON EMICRANIA SENZA AURA

Lo studio e’ stato presentato come poster ( 289-93) al congresso nazionale sisc napoli 2019

Dall’analisi dei risultati emerge vi è la riduzione uguale o superiore al 50% della frequenza di giorni
cefalea/mese nel 31.7% dei pazienti, una significativa riduzione del consumo medio di analgesici e
del punteggio NRS. Non sono stati riferiti effetti collaterali durante la terapia.

Questi dati
dimostrano l’efficacia del  kuzik  come trattamento di profilassi per l’ ESA, associata ad una buona
tollerabilità.

Stresa Headache 2019

KUZIK® IN PROPHYLAXIS OF MIGRAINE: A RETROSPECTIVE OBSERVATIONAL STUDY

Lo studio e’ stato presentato al congresso stresa headache 2019

Our study clearly demonstrated the benefits, safety, and good tolerability of Kuzik® in the prophylaxis of migraine, with and without aura. This study confirms the data obtained in the previous trial and highlights the positive data obtained with Kuzik® twice daily in patients with chronic disease. The use of this medication should be taken in consideration as a good practice in this setting of patients.

KUZIK SI DIMOSTRA EFFICACE NELLA PREVENZIONE DELL’ EMICRANIA SENZA AURA

Our study has demonstrated the efficacy of Kuzik® in the improvement of episodic MO with a reduction at least of 50% in the frequency of attacks per month (51%) and in MIDAS disability score (84%). Kuzik® was well tolerated and allowed a reduction of 50% of symptomatic drug assumptions in 43% of patients treated.
On the basis of these data, we suggest that the use of Kuzik® may have a role in the prophylactic treatment
of MO.

KUZIK SI DIMOSTRA EFFICACE NELLA PREVENZIONE DELL’EMICRANIA SENZA AURA

The journal of headache and pain 2017, 18 (suppl 1):111 p187

Efficacy of KUZIK® in the prophylaxis of migraine without aura: a retrospective observational study


A migraine without aura is the most common type of migraine headache (about 60% to 80% of all migraines). In recent years there is growing interest in the use of nutraceuticals for the prevention of migraine, as there are no specific drugs for this indication. A new kudzu based food supplement (Kuzik), thanks to its innovative mechanism of action, has attracted our interest in this use.

Materials and Methods 
January and April 2017, 30patients with migraine without aura were treated with Kuzik, once a day for 2 months, recruited in various neurological structures including university centers, general hospitals, territorial structures and private outpatient clinic; for all patients, the diary was completed and full fill the headache card (IHS criteria). Patients were evaluated at baseline and after 2 months regarding number of crisis, headache days and VAS (Visual Analogue Scale): data relative to efficacy and tolerability were collected. Patient’s characteristics: 25 female and 5 male; median age 34 (range 22-56); median years of disease 9,4 (range 2-30) and previous treatments 1,2 (range 1-2). At the baseline average number of crisis was 4 (range 2-10) , headache days 7,4 (range 3-14) and medium VAS 7,1 (range 5-10).

Results

Kuzik was well tolerated: in a numerical scale from 1 to 10 the average score was 8 (range 6 -10); the compliance of patients was optimal, no side effect related to product were reported and no weight gain in patients occurred. Regarding efficacy, at the end of treatment, all parameters analyzed were significantly improved: average number of crisis was 1,2 (range 0-3), headache days 2 (range 0-5) and medium VAS 1,9 (range 0-4) .

Conclusions 

Our study has clearly demonstrated the benefits, safety, and good tolerability of Kuzik in the prophylaxis of migraine without aura and the use of this medication should be taken in consideration as a good practice in this setting of patients. Data from our study are encouraging to be confirmed by further investigations.